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Background: Optimal transcorneal penetration is necessary for ocular therapy; meanwhile, 
it is limited by the complex structure and defensive mechanisms of the eye. Antimicrobial 
stability of topical ophthalmic formulations is especially important. According to previous 
studies, the mostly used preservative, benzalkonium-chloride is irritative and toxic on 
corneal epithelial cells; therefore, novel non-toxic, antimicrobial agents are required. In 
this study, prednisolone-containing ophthalmic formulations were developed with expected 
optimal permeation without toxic or irritative effects.
Methods: The toxicity and permeability of prednisolone-containing eye drops were studied 
on a human corneal epithelial cell line (HCE-T) and ex vivo cornea model. The lipophilic 
drug is dissolved by the formation of cyclodextrin inclusion complex. Zinc-containing 
mucoadhesive biopolymer was applied as an alternative preservative agent, whose toxicity 
was compared with benzalkonium-chloride.
Results: As the results show, benzalkonium-chloride-containing samples were toxic on 
HCE-T cells. The biopolymer caused no cell damage after the treatment. This was confirmed 
by immunohistochemistry assay. The in vitro permeability was significantly higher in for-
mulations with prednisolone-cyclodextrin complex compared with suspension formulation. 
According to the ex vivo permeability study, the biopolymer-containing samples had sig-
nificantly lower permeability.
Conclusion: Considering the mucoadhesive attribute of target formulations, prolonged 
absorption is expected after application with less frequent administration. It can be stated 
that the compositions are innovative approaches as novel non-toxic ophthalmic formulations 
with optimal drug permeability.
Keywords: prednisolone, cyclodextrin, ocular drug delivery, mucoadhesion, human corneal 
epithelial cell line, ex vivo cornea model
Introduction
Ocular drug delivery is a difficult challenging task in the field of pharmaceutical research 
and development. The main goal is to meet the requirements of patient-based therapy and 
technological formulation aspects. The special environment of the eye makes the opti-
mization difficult. Several methods have been developed for enhanced ocular drug 
delivery. Mainly topical solutions are in the focus of research laboratories.1–4 Besides 
the advantages of eye drop formulations (self-applicable, non-invasive, convenient, 
economical), many difficulties are known, which need to be overcome (short retention 
time, low drug absorption, and bioavailability and problematic microbiological stability).
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Drug delivery from eye drops is limited because of the 
special anatomical structure and reflex mechanisms, such 
as eye-blinking and lachrymal secretion.5,6 Sufficient 
amounts of the active pharmaceutical ingredient (API) 
need to be ensured on the eye surface, therefore the API 
is able to pass the hydrophilic tear film. The corneal and 
non-corneal pathways for topically applied drug absorp-
tion are complex, and consist of lipophilic and hydrophilic 
layers. For optimal drug penetration the required physico-
chemical characteristics of the drug delivery system must 
be strictly designed. Optimally a lipophilic-hydrophilic 
balance is needed in the system to induce the required 
therapeutic effect without minimal precorneal drug 
elimination.7–10
In ocular postoperative therapy, glucocorticoids are 
applied for treatment and prevention of inflammation. 
These steroids are poorly soluble in water, commonly 
steroid-containing formulations are suspensions on the 
market. Eye drops with prednisolone (PR), prednisolone- 
acetate, dexamethasone, fluorometholone, and fluocino-
lone are licensed worldwide.11–13 PR is mostly used in 
acetate-form as a suspension; however, it is more water- 
soluble than the base form. Problems of suspension for-
mulations are well known. After application, increased 
tear secretion and reflex blinking are induced, causing 
rapid drug elimination from the surface of the eye. 
Increasing the efficiency could be possible with a selection 
of appropriate additives.12
The efficiency can be increased by optimization of the 
amount of dissolved API molecules at the site of drug 
absorption. By using cyclodextrin (CD) derivatives the 
solubility of drug can be increased, therefore a solution 
as a dosage form can be prepared with minimal irritative 
effect and optimal permeation of API.14 CDs are cyclic 
oligosaccharides, which consist of α-(1,4) linked α-D-glu-
copyranose units, which form a water soluble inclusion 
complex with lipophilic molecules. Due to the hydrophilic 
external surface, the molecular complex is soluble in aqu-
eous medium. Thermodynamic interactions are formed 
between the CD and API molecule, and equilibrium is 
created between the free and complexed molecules.15–17 
Due to complex formation, a more dissolved, lipophilic 
API molecule can permeate through the epithelium, mean-
while the hydrophilic cyclodextrin is eliminated.4,16 
Considering the toxicological toleration, hydroxypropyl-, 
sulfobutyl-ether-β-CD, and hydroxypropyl-γ-CD deriva-
tives are mostly applied in ocular drug delivery. The 
amount of CD concentration must be set strictly to ensure 
the optimal drug permeation. Unnecessarily high amount 
restricts the drug permeation, meanwhile low concentra-
tion cannot keep the API in solution, which causes limited 
efficiency.18,19
Besides enhancement of permeation, increasing the 
residence time on the eye surface induces a higher ther-
apeutic effect. Residence time is increasable by mucoad-
hesive polymers, which can ensure prolonged drug 
absorption; therefore, less frequent administration is 
needed during the therapy. By addition of these com-
pounds, the viscosity is increased which is also favorable 
considering the increment of contact time on the eye 
surface.20–22 However, if the viscosity of the applied for-
mulation significantly differs from the tear, the defensive 
mechanisms of the eye are induced, thus the elimination 
rate of the API will be increased. Besides the increased 
viscosity, mucoadhesion also provides enhanced retention 
on the eye surface due to the interpenetration of proteo-
glycan and polymer chains.23,24 Nowadays, mucoadhesive 
biopolymers, such as hyaluronic acid (HA), are widely 
used in ophthalmic formulations. As a biocompatible poly-
mer, HA is tolerable, non-toxic, and protects the cornea 
with a proliferative effect.25,26
The microbiological stability is especially important 
in the case of ophthalmic formulations, because of the 
special sensitivity of the eye. Mostly, benzalkonium- 
chloride (BK) is applied as a preservative compound, 
meanwhile its destructive effect on corneal epithelial 
cells is proven. BK damages the eye barrier through 
breaking the DNA single- and double-strands in the 
epithelial cells. Application of BK-containing eye 
drops may induce irritation and high lachrymal 
secretion.27,28 As an alternative preservative, Zn2+ ion- 
containing systems can be added. In aqueous environ-
ment, the dissolved Zn2+ ion destabilizes the cell wall of 
microbes. Therefore zinc-containing compounds like 
zinc-hyaluronate (ZnHA) and zinc-gluconate (ZnGlu) 
may ensure the antimicrobial stability in the formulation 
with less irritative and toxic effect in the corneal epithe-
lial cells in comparison with BK.20,29
Previously, formulation and investigation of innovative 
eye drop were published by our research group, where 
innovative PR-containing ophthalmic solution was devel-
oped in aqueous medium by the addition of CD derivatives 
and ZnHA-ZnGlu system. The physiological parameters 
(surface tension, pH, osmolality) were set with optimized 
mucoadhesive, rheological, and preservative attributes.12 
The aim of this study was to continue and complete the 
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research by investigating the cytotoxicity and API perme-
ability of the formulation on an in vitro human corneal cell 
line and ex vivo, porcine cornea model.
Materials and Methods
Materials
PR was purchased from Henan Lihua Pharmaceutical 
Company (Henan, China). hydroxypropyl-γ-cyclodextrin 
(HPGCD) was donated by Cyclolab Ltd. (Budapest, 
Hungary), ZnHA and ZnGlu from Gedeon Richter Plc 
(Budapest, Hungary). Hydroxypropyl-β-cyclodextrin 
(HPBCD) was obtained from Wacker-Chemie GmbH 
(Munich, Germany). Dimethyl sulfoxide (DMSO), BK, 
NaCl, boric acid, and borax (for borate buffer) were 
obtained from Molar Chemical Ltd. (Halásztelek, 
Hungary), KCl, NaHCO3, D-glucose monohydrate from 
Kemika (Zagreb, Croatia), CaCl2 × 2H2O and MgCl2 × 
6H2O from Sigma-Aldrich, Chemie GmbH (Steinheim, 
Germany). Ringer-buffer was used as medium during the 
experiments. The pH of Ringer buffer was set to 7.4.
Sample Preparation
0.1% PR was used as API. Defined amounts of 
HPGCD or HPBCD were dissolved in borate buffer 
(prepared by water for injection filtered on 0.22 µm 
membrane filter). After addition of PR products were 
sonicated for 10 minutes, until total dissolution of API. 
Then 0.5% ZnHA and 0.5% ZnGlu was added to the 
system. Osmolality was set with NaCl to about 300 
mOsm/kg, the pH was about 6.20 in every formulation. 
Every eye drop was prepared in aseptic environment. 
The containers were stored in the fridge for at least 24 
hours for completely wetting of ZnHA. Final composi-
tion is shown in Table 1.
Preparation of Human Corneal Epithelial 
Cell Line (HCE-T) Model
Human corneal epithelial cells (HCE-T; RCB 2280; RIKEN 
BRC, Tsukuba, Japan) were immortalized by transfection with 
a recombinant SV40-adenovirus vector, established and char-
acterized by Araki-Sasaki.30 The cells were grown in 
Dulbecco’s Modified Eagle’s Medium/F-12 (Gibco, Life 
Technologies, Carlsbad, CA, USA) supplemented with 10% 
fetal bovine serum (Gibco), 0.5% DMSO, 5 µg/mL recombi-
nant human insulin, and 10 ng/mL recombinant human epi-
dermal growth factor (EGF) in a humidified incubator with 5% 
CO2 at 37°C. All plastic surfaces were coated with 0.05% rat 
tail collagen in sterile distilled water before cell seeding in 
culture dishes. The culture medium was changed every second 
day. The air–liquid interface is crucial for the development of a 
tight multilayer epithelium in HCE-T cells.31 HCE-T cells 
were cultured first in liquid–liquid condition for 5–8 days. 
To create the air–liquid condition the medium from the 
upper compartment was removed and only 1 mL of medium 
was added to the lower compartment to keep the liquid level at 
the appropriate height for the next 5–8 days. To measure 
TEER cells were fed with 500 µL medium in the upper 
compartment every second day.
Treatment of Cultured Cells
The final concentration of the PR in the formulations for 
cell culture experiments was 100 µg/mL. The formulations 
were diluted in Ringer buffer (pH=7.4) (150 mM NaCl, 
2.2 mM CaCl2, 0.2 mM MgCl2, 5.2 mM KCl, 5 mM 
glucose, 6 mM NaHCO3). We tested the following sam-
ples (Table 2).
Cell Viability Measurement by Impedance
Impedance was measured at 10 kHz by an RTCA SP 
instrument (ACEA Biosciences, San Diego, CA, USA). 
Table 1 Composition of Target Eye Drop Formulation
Materials Concentration
Prednisolone 0.1%
Hydroxypropyl-β-cyclodextrin or hydroxypropyl- 
γ-cyclodextrin
5 mM or 4 mM
Zinc-hyaluronate 0.5%
Zinc-gluconate 0.5%
Borate buffer Quantum satis
Sodium-chloride Quantum satis
Water for injection Quantum satis
Table 2 Composition of Investigated Samples by Toxicity and 
Permeability Studies. Defined Amounts Were Completely 
Dissolved or Suspended in Ringer Buffer
For Cell Viability 
Measurements
For Permeability Assay
I. PR/HPBCD/ZnHA/ZnGlu F1 PR
II. PR/HPGCD/ZnHA/ZnGlu F2 PR/HPBCD
III. PR/HPBCD/BK F3 PR/HPGCD
IV. PR/HPGCD/BK F4 PR/HPBCD/ZnHA/ZnGlu
V. ZnHA/ZnGlu F5 PR/HPGCD/ZnHA/ZnGlu
VI. BK
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This method is label-free, non-invasive, and monitors cell 
adherence, growth, and viability real time. We have suc-
cessfully tested the cellular effects of pharmaceutical exci-
pients and peptides by impedance kinetics in our previous 
studies.32–34 For background measurements 50 μL of cell 
culture medium was added to the wells, then cells were 
seeded at a density of 5×103 cells/well to 96-well plate 
with gold electrodes (E-plate 96, ACEA Biosciences) 
coated with collagen. Cells were cultured for 4–5 days in 
a CO2 incubator at 37°C and monitored every 10 minutes 
until the end of experiments. Cells were treated at the 
beginning of the plateau phase of growth. The treatment 
solutions were dissolved in Ringer buffer. Triton X-100 
(TX-100) detergent (1 mg/mL) was used as a reference 
compound to induce cell toxicity. Cell index was defined 
as Rn-Rb at each time point of measurement, where Rn is 
the cell-electrode impedance of the well when it contains 
cells and Rb is the background impedance of the well with 
the medium alone.
Immunohistochemistry
To evaluate morphological changes in HCE-T cells caused by 
the different formulations, cell viability assay was followed 
by immunostaining for junctional proteins zonula occludens 
protein-1 (ZO-1), occludin, β-catenin, and E-cadherin. Cells 
were grown on glass coverslips (Menzel-Glaser, 
Braunschweig, Germany) at a density of 4×104 cells/cover-
slips and treated with different formulations containing PR 
for 30 minutes. After the treatment, coverslips were washed 
with phosphate buffer (PBS) and the cells were fixed with 
3% paraformaldehyde solution for 15 minutes at room tem-
perature. The cells were permeabilized by 0.2% TX-100 
solution for 10 minutes and the non-specific binding sites 
were blocked with 3% bovine serum albumin in PBS. 
Primary antibodies rabbit anti-ZO-1 (AB_138452, 1:400; 
Life Technologies, Carlsbad, CA, USA), rabbit anti-β-cate-
nin (AB_476831, 1:400), rabbit anti-occludin (AB_2533977, 
1:100; Life Technologies), and mouse anti-E-cadherin 
(AB_397580, 1:400; Life Technologies) were applied as 
overnight treatment. Incubation with secondary antibodies 
Alexa Fluor-488-labeled anti-mouse (AB_2534088, 1:400; 
Life Technologies) and anti-rabbit IgG Cy3 conjugated 
(AB_258792, 1:400) lasted for 1 hour. Hoechst dye 33,342 
was used to stain cell nuclei. After mounting the samples 
(Fluoromount-G; Southern Biotech, Birmingham, IL, USA) 
staining was visualized by a Visitron spinning disk confocal 
system (Visitron Systems GmbH, Germany).
Permeability Study on HCE-T Cell 
Culture Model
Transepithelial electrical resistance (TEER) reflects the 
tightness of the intercellular junctions closing the paracel-
lular cleft, therefore the overall tightness of cell layers of 
biological barriers. TEER was measured to check the 
barrier integrity by an EVOM volt-ohmmeter (World 
Precision Instruments, Sarasota, FL, USA) combined 
with STX-2 electrodes, and was expressed relative to the 
surface area of the monolayers as Ω × cm2. TEER of cell- 
free inserts was subtracted from the measured data.
HCE-T cells were seeded at a density of 105 cells onto 
Transwell inserts (polycarbonate membrane, 0.4 µm pore 
size, 1.12 cm2 surface area; 3401, Corning Life Sciences, 
Tewksbury, MA, USA) and cultured for 5–8 days at 
liquid–liquid and for 5–8 days at air–liquid interface. The 
culture medium was changed and TEER was checked 
every second day.
For the permeability experiments the inserts were 
transferred to 12-well plates containing 1.5 mL Ringer 
buffer in the acceptor (lower/basal) compartments. In the 
donor (upper/apical) compartments 0.5 mL buffer was 
pipetted containing different formulations (F1–F5) of PR 
for 30 minutes. To avoid unstirred water layer effect, the 
plates were kept on a horizontal shaker (120 rpm) during 
the assay. Samples from both compartments were collected 
and the PR concentration was detected by HPLC.
To determine the tightness of the cornea epithelial 
culture model two marker molecules were tested.34 In the 
donor compartments 0.5 mL buffer containing fluorescein 
(10 μg/mL; Mw: 376 Da) and Evans blue labeled albumin 
(167.5 μg/mL Evans blue dye and 10 mg/mL bovine 
serum albumin; Mw: 67.5 kDa) was added. The inserts 
were kept in the multiwell plates on a horizontal shaker 
(120 rpm) for 30 minutes, then the concentrations of the 
marker molecules in the samples from the compartments 
were determined by a fluorescence multiwell plate reader 
(Fluostar Optima, BMG Labtechnologies, Germany; fluor-
escein: excitation wavelength: 485 nm, emission wave-
length: 520 nm; Evans-blue labeled albumin: excitation 
wavelength: 584 nm, emission wavelength: 680 nm).
The apparent permeability coefficients (Papp) were cal-
culated as described previously.34 Briefly, cleared volume 
was calculated from the concentration difference of the 
tracer in the acceptor compartment (Δ[C]A) after 30 min-
utes and donor compartments at 0 hour ([C]D), the volume 
of the acceptor compartment (VA; 1.5 mL) and the surface 
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area available for permeability (A; 1.1 cm2) using 
Equation 1:
Pappðcm=sÞ ¼
Δ C½ �A � VA
A� C½ �D � Δt
(1) 
Ex vivo Permeability Assay
The ex vivo permeability model was published previously by 
Juretić et al.35,36 Fresh porcine eyes were collected from 
Large White Pigs (weight 90–115 kg, male and female, 6–7 
months) from a local slaughterhouse. Enucleated eyeballs 
were washed by isotonic saline solution (NaCl, 0.9%; B. 
Braun, Melsungen, Germany) and stored in Ringer buffer 
in a container held on ice until application. Transport and 
excision were performed within 2 hours after the death of 
animals. Excised corneas were placed into vertical diffusion 
chambers (Standard Vertical Ussing/Diffusion Chambers, 
made of acrylic with 0.64 cm2 diffusion surface, Harvard 
Apparatus, Holliston, MA, USA). The epithelial side of the 
cornea was faced to the donor phase of the system. Donor 
and acceptor phase volume were equally 3.5 mL. After 30 
minutes incubation of corneas (Ringer buffer, 37°C), the 
donor compartment was removed, and 3.5 mL sample was 
injected. Then 500 µL samples were collected from the 
acceptor compartment at defined time intervals (0 minutes, 
30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, and 5 hours) and 
refilled with 500 µL Ringer-buffer at each sample collection. 
Continuous oxygenation was ensured during the experiment 
for mixing of the system and mimicking physiological cir-
cumstances for the tissue. Six parallels were measured for 
each type of formulation (F1–F5). PR content of samples was 
analyzed by HPLC. Apparent permeability was calculated at 
each sample by using Equation 1.
TEER Measurement in ex vivo Model
During the ex vivo permeability assay, the integrity of 
porcine corneas was monitored by TEER measurement, 
to check whether the compounds affect the barrier proper-
ties of the model. Ag/AgCl electrodes were used con-
nected with Millicell® ERS-2 Epithelial Volt-Ohm Meter 
(EMD Millipore Corporation, Billerica, MA, USA). The 
resistance was measured at 0, 15, 150, and 300 minutes in 
each cornea containing vertical diffusion chambers. Blank 
resistance was measured and subtracted to obtain exactly 
the TEER of ex vivo cornea-based model.
Quantification by High-Performance 
Liquid Chromatography
The quantitative measurement of PR was performed by 
high-performance liquid chromatography (HPLC) using 
Agilent Infinity 1260 (Agilent, Santa Clara, CA, USA). 
Phenomenex Gemini NX C18 column (150x4.6 mm, 5 
µm) was used with the official method of European 
Pharmacopoeia.37 The following conditions were applied 
during the analysis: highly purified and filtered water in 
channel A, HPLC grade acetonitrile/HPLC grade methanol 
50%/50% in channel B, 1 mL/min flow rate, 25°C tem-
perature. Gradient elution was used for the separation. 
Samples were collected from in vitro HCE-T and ex vivo 
cornea models; 20 µL volume of samples was injected and 
analyzed on 254.4 nm wavelength.
Statistical Analysis
All data presented are means±SD. The values were com-
pared using the one-way ANOVA followed by Dunnett 
test by GraphPad Prism 5.0 software (GraphPad Software 
Inc., San Diego, USA). Changes were considered statisti-
cally significant at P<0.05.
Results
Barrier Properties of the Cornea 
Epithelial Cell Culture Model
HCE-T cell layers showed good barrier properties as 
reflected by the TEER values (246±7 Ω×cm2, n=3) after 
6 days of air-liquid interface condition (Figure 1A). The 
permeability of HCE-T cell layers was low (Figure 1B) for 
the hydrophilic marker molecules fluorescein (Papp: 1.05 
±0.11×10−6 cm/s) and the large biomolecule albumin 
(Papp: 0.10±0.04×10−6 cm/s).
Cell Viability Assay
Impedance measurement, as a sensitive method to detect 
cellular effects, showed significant cell damage after treat-
ment with all three formulations containing BK (III, IV, 
VI). PR containing formulations with HPBCD, HPGCD, 
ZnHA, and ZnGlu did not show any cytotoxic effect. The 
normalized cell index was significantly higher in ZnHA/ 
ZnGlu containing sample (V) than in formulation with BK 
(VI). As a comparison, maximal toxicity was detected in 
cells treated with the reference damaging agent Triton X- 
100 detergent (Figure 2).
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Immunohistochemistry
The cornea epithelial cells formed a tight paracellular barrier 
visualized by the localization of the junctional proteins 
ZO-1, β-catenin, E-cadherin, and occludin. The cells were 
tightly apposed, and all junctional proteins were localized at 
the intercellular connections forming pericellular belts in the 
Figure 1 (A) Electrical resistance values of the HCE-T cornea epithelial cell layers cultured for 8 days at liquid–liquid interface and for an additional 8 days at air–liquid 
interface (ALI). (B) Permeability of HCE-T epithelial cell layers for fluorescein (SF) and Evans blue labeled albumin (EBA) marker molecules. Values are presented as means 
±SD (n=4).
Figure 2 Cell viability of HCE-T corneal epithelial cells after 1-hour treatment with formulations measured by impedance. Values are presented as means±SD (n=6–12). 
Statistical analysis: ANOVA followed by Dunnett’s test (*P<0.05; ***P<0.001 compared to control). 
Abbreviation: Tx-100, Triton X-100.
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control groups (Figure 3). Morphological change can be 
observed in the case of BK-containing sample (VI) by the 
localization of E-cadherin protein. No major morphological 
change was seen for the treatment of other groups.
Permeability Study on HCE-T Cell 
Culture Model
The permeability of PR given in different formulations was 
tested on the HCE-T cell model (Figure 4). After 30-minute 
treatment only dissolved PR-CD complex containing formu-
lation 2 (F2) and formulation 3 (F3) showed significantly 
higher Papp values (F2: 5.97×10−6 cm/s, F3: 5.97×10−6 cm/s) 
compared with PR suspension (F1: 5.02×10−6 cm/s). Papp 
values were minimally lower in ZnHA/ZnGlu-containing 
formulations (F4: 5.59×10−6 cm/s, F5: 5.31×10−6 cm/s). 
The model showed low Papp values for the two hydrophilic 
paracellular marker molecules indicating a good barrier.
Ex vivo Permeability Assay
Permeability of PR was tested on an ex vivo porcine cornea 
model in the case of previously mentioned formulations 
(F1–F5) (Figure 5). In the case of PR-HPBCD (F2), perme-
ability was higher (2.05×10−7 cm/s) compared with PR- 
containing suspension (F1, 1.79×10−7 cm/s). Permeability 
in PR-HPGCD (F3) complex-containing samples was lower 
(1.31×10−7 cm/s). Considering the relatively high standard 
deviations in F1–F3, no significant difference can be stated 
between their Papp values. In the presence of ZnHA/ZnGlu 
(F4–F5), significantly lower permeability values were mea-
sured (F4: 1.05×10−7 cm/s, F5: 0.98×10−7 cm/s). The mon-
itored TEER values were in the range of 1052–2818 Ω cm2.
Discussion
Glucocorticoids are widely used as anti-inflammatory 
drugs in ophthalmology, mostly applied in the therapy 
of diseases affecting the anterior segment of the eye. Due 
to the poor water solubility of steroids, they can be 
found in suspension formulations on the market. 
Disadvantageous attributes of suspensions like irritation 
on the eye may induce fast elimination of drug, therefore 
frequent application is needed to ensure the proper 
therapy.4,11 Our aim was a pharmaceutic formulation 
development, where PR is in water dissolved form with 
expected increased therapeutic effect. In the early phase 
of the study, PR-CD inclusion complex was formed and 
dissolved in a borate-buffer-based environment. The for-
mulations contain ZnHA and ZnGlu to increase the resi-
dence time by mucoadhesion and the antimicrobial 
Figure 3 Effects of PR and pharmaceutical excipients containing formulations on junctional morphology of HCE-T corneal epithelial cells. Immunostaining for zonula 
occludens-1 (ZO-1), occludin tight junction proteins and β-catenin, E-cadherin adherens junction proteins after 1-hour treatment. Red and green color: immunostaining for 
junctional proteins. Blue color: staining of cell nuclei. Bar: 40 µm.
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stability by the preservative effect Zn2+ ion. In this 
ophthalmic solution, the physiological parameters were 
set. Previous investigations confirmed that the formula-
tions have adequate mucoadhesiveness with suitable 
antimicrobial stability (Ph Eur. requirement B).12 
Continuing the project, our aim was to test the formula-
tions for toxicity and permeability on an in vitro cell 
culture model and ex vivo cornea to predict the safety 
and expected absorption after topical application on 
the eye.
An immortalized human corneal epithelial cell line was 
used by in vitro toxicity and permeability tests. The cell 
culture was established by Araki-Sasaki, whose optimal 
grown attributes are favorable in the studies of ophthalmic 
formulations. The toxicity was investigated by impedance 
measurement after the treatment of several types of 
formulations. According to the calculated normalized cell 
index, ZnHA-ZnGlu-containing samples are not toxic, 
meanwhile BK-containing samples show significantly 
lower values and the toxic effect can be observed on the 
HCE-T cells. The toxicity of BK-containing formulations 
was also demonstrated by immunohistochemistry. Major 
morphological changes were seen on E-cadherin junctional 
protein by the cells treated by BK-containing formulations. 
In the case of target eye drops formulated with ZnHA- 
ZnGlu, no morphological change and no toxic effect were 
detected on the cell culture. It can be stated that the ZnHA- 
ZnGlu combination is a non-toxic alternative preservative 
system, which is tolerable on HCE-T cells in the applied 
concentration. The results of BK-containing samples con-
firmed the previously published toxic and expected irrita-
tive effect on the eye surface.
Furthermore, the permeability of PR was tested on 
HCE-T model in different formulations. The applied in 
vitro model is suitable for the prediction of drug absorp-
tion through the lipophilic epithelial cell layer of the 
cornea. It needs to be mentioned that this in vitro model 
only shows the permeation through the epithelial layer, for 
prediction of transcorneal permeation, ex vivo cornea 
model is preferred. Meanwhile, testing the samples on 
cell culture, the absorption through the first obstacle of 
corneal barrier can be simulated. PR-CD complex-contain-
ing solutions and PR-CD-ZnHA-ZnGlu-containing target 
formulations were studied compared with sample which 
contains the same amount of PR in suspension form. The 
electric resistance was monitored, and it confirmed the 
barrier integrity of cell layers. The permeability was sig-
nificantly higher in samples containing the dissolved PR- 
CD complex compared with the suspension. Because the 
concentration of dissolved API is higher in PR-CD solu-
tions, and higher towards the corneal epithelial cell layer, 
faster drug permeation is expected through the epithelial 
layer. In the target formulations with biopolymer, the per-
meability is minimally lower, due to the diffusion restric-
tive effect of the polymer structure.
Transcorneal permeation of PR was investigated by ex 
vivo porcine cornea model. Freshly resected corneas were 
put into vertical diffusion chambers. O2 was continuously 
circulated in the chambers to ensure the respiration of cor-
nea, and the donor and receptor phases are mixed during the 
experiment. The same compositions were tested as in the 
HCE-T model. The monitored TEER was increased during 
the experiment, the integrity of the cornea was acceptable, 
samples did not cause damage and toxic effects on the 
Figure 4 Permeability of PR (100 µg/mL in each formulations) (F1–F5) across HCE- 
T epithelial cell layers (30-minute assay). Values for paracellular permeability mar-
kers fluorescein (SF) and Evans blue labeled albumin (EBA) are also shown. 
Statistical analysis: ANOVA followed by Dunnett’s test. ***P<0.001. Values are 
presented as means±SD (n=4). P<0.001 compared to F1.
Figure 5 Permeability of PR in different formulations (F1–F5) across in ex vivo 
porcine cornea model. Statistical analysis: ANOVA followed by Dunnett’s test. 
*P<0.05 compared to F1. Values are presented as means±SD (n=6).
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barrier, which can affect the permeability of PR. Compared 
with published results, these values meet the requirement of 
barrier properties.35,37 According to the results, no signifi-
cant difference was found between the eye drop suspension 
and solutions. Permeability values were significantly lower 
in ZnHA-ZnGlu-containing formulations in comparison 
with the suspension form. Considering the continuous mix-
ing, vertical position, and complexity of porcine cornea, the 
optimal attributes are not observed in this model in solution- 
based samples. The permeability is lower in target formula-
tions because polymer structure affects the drug diffusion 
negatively; however, the retention time is increased on the 
eye surface due to the increased viscosity and mucoadhe-
sion. In the case of ex vivo study the whole porcine cornea is 
used, which is complex, formed by lipophilic and hydro-
philic layers. Therefore, the difference shall be observed in 
the permeability on in vitro HCE-T and ex vivo porcine 
cornea models. The formulations can be optimal in vivo, 
because less irritation and lachrymal secretion are expected 
due to the not irritative solution form of eye drops.
As the eye drop contacts for longer time, reflex lachry-
mal secretion and eye blinking are limited, prolonged drug 
absorption is expected after administration, which results 
in less frequent application. We assume that the perme-
ability of PR is optimal in the target formulations, which 
may result in an enhanced therapeutic effect.
Conclusions
In summary, novel ophthalmic formulations were devel-
oped, where PR is dissolved in a water-based environ-
ment as CD inclusion complex. Eye drops contain a 
mucoadhesive and alternative preservative ZnHA- 
ZnGlu system. We found that the formulations are 
non-toxic with optimal permeability according to the 
results of in vitro and ex vivo models. These composi-
tions are promising for overcoming the challenges of 
ocular drug delivery by increased bioavailability, 
ensured microbiological stability, minimal irritation, 
and acceptable patient compliance.
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